All Articles

Starton Therapeutics files patents to combine its continuous low-dose therapy, STAR-LLD, with CAR-T, aiming to enhance cancer-killing power and durability.

Taiwanese biotech GNTbm's oral drug GNTbm-38, which turns 'cold' tumors 'hot', will begin Phase 1 trials for advanced and refractory cancers.

Iconic Australian bootmaker R.M.Williams expands its partnership with Bamboo Rose, leveraging AI-powered planning to modernize its global operations.

With a key federal security clearance, Dejero's connectivity platform is now available for U.S. agencies, promising enhanced security and field operations.

A new partnership sees Veritone's AI unlock The Washington Post's video vault, aiming to monetize history while protecting journalistic integrity.

Spirent's new SimXTRACT tool promises to slash PNT development time by bringing real-world satellite signal complexity into the controlled lab environment.

AI drug discovery firm Proxima appoints three titans of science to its board, signaling a major push in proximity therapeutics to rewrite medicine's rules.

A new report reveals why distributors are holding more stock, risking cash flow to battle volatility and win customers in a fiercely competitive market.

IDOC's acquisition of GSRx signals a major strategic move, promising benefits for independent optometrists but raising questions about industry consolidation.

New study shows an AI platform matches expert radiologists in tumor measurement, promising a new era of precision and consistency in breast cancer surgery.

With FDA Breakthrough status for its MASH drug, a new CEO, and a fortified balance sheet, Altimmune is poised to take on serious liver disease and addiction.

With no approved treatments for the deadly pregnancy complication preeclampsia, one company's novel drug is now advancing to a crucial new clinical trial.

A new platform in Uzbekistan merges traditional banking with crypto under a state-led framework, offering a potential blueprint for global digital finance.

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

With women as just 4% of skilled trade workers, a Tulsa company is leading a charge to recruit them into high-paying, in-demand careers.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

Montreal's Equinoxe LifeCare acquires Ottawa's Choice Homecare, a strategic move responding to a massive care gap for Canada's aging population.

Beating Wall Street estimates with historic gross profits, the chipmaker leverages new capital and key partnerships to push its ultra-low-power tech deeper into AI.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With a new outpatient model, NexCure aims to bring life-saving cancer treatments like CAR-T closer to home, tackling a major healthcare bottleneck.